Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$45213 of $63500 - as of 2024-10-31
71%
ADxS.org Logo
ADxS.org Logo
Search Donations Addresses Recent changes ADHS-Forum Deutsche Version
Register

Already have an account? Login

Header Image
Quinpirole for ADHD

Sitemap

The ADxS.org project
Abstract from ADxS.org
Symptoms
Consequences of ADHD
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment: Guide and Effect size
Treatment: Medication for ADHD
Treatment: Medication for ADHD - Overview
Choice of medication for ADHD or ADHD with comorbidity
Dosing of medication for ADHD
Suitable medication for ADHD
Experimental medication for ADHD
Sleep disorder-related medication for ADHD
Appetite-enhancing medication for ADHD
Medication for ADHD in development
Less suitable medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effect in ADHD
Non-drug treatment
Addresses
This and that about ADHD
Tests and surveys
Forum

Quinpirole for ADHD

Previous page Next page

There is no description of a sensible use of quinpirole for ADHD.
The presentation is only for the sake of completeness.

Quinpirole is a selective D2 and D3 agonist.1
Quinpirole reduces dopamine levels in the left PFC, but increases them in the striatum and amygdala.2

Hypermotor activity and compulsive behavior are intensified.

Whether this increase in hypermotor activity also occurs in ADHD-HI/ADHD-C sufferers must be questioned. Hyperactivity is located in the striatum. However, symptoms are caused by suboptimal neurotransmitter levels, in this case hyperactivity caused by a lack of dopamine as well as an excess of dopamine.
If quinpirole increases the dopamine level in the striatum, it is plausible that hyperactivity symptoms occur in those not affected.
In ADHD-HI and ADHD-C, however, there is a dopamine deficit in the striatum. It should therefore follow that quinpirole eliminates this deficit and at the same time reduces hyperactivity.

In ADHD, a dopamine deficiency in the PFC is also assumed. A further reduction in dopamine levels would therefore be detrimental.
However, the medial and right PFC is primarily affected in ADHD.
How harmful the reduction in dopamine levels in the left PFC caused by quinpirole is in ADHD remains to be seen.

In addition, quinpirole - as well as aripiprazole (Abilify), a partial D2 receptor agonist - reduces cue-induced craving for cocaine in adult (but not in young) rats and can thus help with addiction problems.3

Another study in rats showed significant THC-like effects of quinpirole when the metabolic degradation of anandamide is inhibited, supporting the hypothesis that these effects of quinpirole are mediated by cannabinoid CB1 receptors.4

In DAT-KD rats, which have a dopamine transporter effect reduced to 10 %, quinpirole reduced hyperactivity, as did the D2 agonist apomorphine and amphetamine as an indirect dopamine receptor agonist.5

  1. https://en.wikipedia.org/wiki/Quinpirole ↥

  2. Sullivan, Talangbayan, Einat, Szechtman (1998): Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience. 1998 Apr;83(3):781-9 ↥

  3. Zbukvic, Ganella, Perry, Madsen, Bye, Lawrence, Kim (2016): Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats; Cereb. Cortex (2016) 26 (6): 2895-2904. doi: 10.1093/cercor/bhw051 ↥

  4. Solinas, Tanda, Wertheim, Goldberg (2010): Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D2-induced formation of anandamide; Psychopharmacology (Berl). 2010 Apr; 209(2): 191–202. doi: 10.1007/s00213-010-1789-8; PMCID: PMC2834964; NIHMSID: NIHMS180022 ↥

  5. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R (2001): Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1982-7. doi: 10.1073/pnas.98.4.1982. PMID: 11172062; PMCID: PMC29368. ↥

Diese Seite wurde am 25.03.2024 zuletzt aktualisiert.
Previous page Next page